Prospective, Multicenter, Open-label Phase IV trial of Trifluridine/Tipiracil (FTD/TPI) to Evaluate the Health-related Quality of Life in Patients with Metastatic Colorectal Cancer (mCRC)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 19 Jan 2019
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms TALLISUR
- Sponsors Servier Deutschland
- 19 Jan 2019 160 patients recruited (17 Sep 2018) as per trial design presented at the 2019 Gastrointestinal Cancers Symposium.
- 15 Nov 2018 Planned End Date changed from 30 Aug 2019 to 31 Dec 2019.
- 15 Nov 2018 Status changed to recruiting.